Crosslinking impacts the recycling of HER2:zanidatamab complexes, leading to increased receptor internalization and degradation21 which, combined with direct inhibition of HER2 signaling pathways, promotes inhibition of growth of HER2-expressing cancer cells. This evidence concerns the gene ERBB2 and cancer.